Roic AI
Search
/
Search
/
Pricing
Sign inSign up

You're using the beta version. You're using the beta version of the new website.

SummaryFinancialsRatiosTranscriptsClassic View

Footer

Found an error or have an idea?
or write us an email to [email protected]

Company

  • About
  • Pricing
  • Blog

Support

  • Knowledge Base
  • FAQ

Legal

  • Privacy Policy

© 2023 Roic AI, Inc. All rights reserved.

Business
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Company News

  • Investor's Business Daily

    a month ago

    Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+

  • Investor's Business Daily

    a month ago

    Amgen Stock Scores Relative Strength Rating Upgrade; Hits Key Benchmark

  • Investor's Business Daily

    a month ago

    Axsome Therapeutics Stock Earns Relative Strength Rating Upgrade

  • Investor's Business Daily

    a month ago

    ACELYRIN Stock Scores Relative Strength Rating Upgrade; Hits Key Threshold

  • Investor's Business Daily

    a month ago

    Exelixis Stock Sees Rising Relative Strength Rating

  • Dow Jones Newswires

    2 months ago

    Catalyst Pharmaceuticals: Patrick McEnany to Retire as CEO by Year-End >CPRX

  • Investor's Business Daily

    4 months ago

    The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

  • Investor's Business Daily

    4 months ago

    Ultragenyx Pharm Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

  • Investor's Business Daily

    5 months ago

    Catalyst CEO Says 'We Hit The Ball Out Of The Park,' But Shares Of IBD 50 Stock Crash

  • Investor's Business Daily

    5 months ago

    Cassava Sciences Stock Clears Benchmark, Hitting 80-Plus RS Rating

  • Dow Jones Newswires

    5 months ago

    Catalyst Pharmaceuticals 1Q EPS 26c >CPRX

  • Investor's Business Daily

    5 months ago

    Immunogen Stock Shows Market Leadership With Jump To 99 RS Rating

  • Investor's Business Daily

    5 months ago

    How To Invest: Accelerating Profit Growth Often Marks Winning Stocks Before Their Big Runs

  • Investor's Business Daily

    6 months ago

    Vertex Pharmaceuticals Stock Sees Composite Rating Edge Up To 96

  • Investor's Business Daily

    6 months ago

    No. 1 Biotech Catalyst Pharma Surges On 2023 Expectations

  • Barron's

    2 years ago

    Companies Push Back Against Cost of Robinhood Stock Giveaway

  • The Wall Street Journal

    2 years ago

    Regulators Eye a Robinhood Marketing Ploy: Free Shares

C

Catalyst Pharmaceuticals, Inc.

CN2 GF

CN2 GFCatalyst Pharmaceuticals, Inc.DEGF
FIGI: BBG000H5MZ52
  1. United States Stocks
  2. •

    Healthcare
  3. •

    Biotechnology

11.26

EUR
+0.04
(+0.31%)
Catalyst Pharmaceuticals, Inc.
CN2:GF
(FRANKFURT)

Recent

price

11.26

P/E

ratio

10.23

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
USD
- -
- -
- -
0.03
- -
- -
- -
- -
- -
- -
- -
0.00
0.99
1.15
1.36
2.07
2.89
Revenue per ShareRevenue per Share
-0.33
-0.81
-0.48
-0.22
-0.29
-0.14
-0.27
-0.24
-0.25
-0.22
-0.21
-0.33
0.31
0.72
0.38
0.80
1.10
Basic EPS, GAAPBasic EPS, GAAP
-0.36
-0.63
-0.51
-0.20
-0.23
-0.17
-0.22
-0.20
-0.22
-0.22
-0.16
-0.25
0.34
0.43
0.57
1.12
1.18
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per ShareDividend per Share
-0.79
-1.45
-1.53
-1.63
-1.54
-1.02
-1.00
-1.01
-1.09
-1.30
-1.23
-1.56
-1.24
-0.52
-0.25
0.47
1.10
Book Value per ShareBook Value per Share
1.30
0.75
0.42
0.28
0.15
0.35
0.40
0.51
0.67
0.47
0.79
0.49
0.85
1.63
2.01
2.55
1.88
Tangible Book Value per ShareTangible Book Value per Share
13
13
15
19
22
30
45
64
81
83
86
103
103
104
103
103
105
Basic Weighted Avg SharesBasic Weighted Avg Shares
- -
- -
- -
0
- -
- -
- -
- -
- -
- -
- -
1
102
119
141
214
303
Sales/Revenue/TurnoverSales/Revenue/Turnover
- -
- -
- -
-823.01
- -
- -
- -
- -
- -
- -
- -
-7,059.03
31.11
34.69
37.20
47.54
45.62
Operating Margin (%)Operating Margin (%)
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
1
16
Depreciation ExpenseDepreciation Expense
-4
-11
-7
-4
-6
-4
-12
-16
-20
-18
-18
-34
32
75
39
83
116
Net Income, GAAPNet Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
4.59
- -
25.03
20.66
20.22
Effective Tax Rate (%)Effective Tax Rate (%)
- -
- -
- -
-819.36
- -
- -
- -
- -
- -
- -
- -
-6,800.70
31.16
62.97
28.03
38.79
38.14
Profit Margin (%)Profit Margin (%)
16
10
8
5
5
15
23
38
56
39
81
46
87
136
183
263
188
Working CapitalWorking Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
4
4
3
LT DebtLT Debt
16
11
8
6
4
15
21
35
55
39
81
51
88
170
207
300
375
Total EquityTotal Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
43.10
- -
20.63
30.83
34.97
Return on Invested Capital (%)Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-22.13
- -
-104.48
521.59
182.22
Return on Capital (%)Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
194.13
Return on Common Equity (%)Return on Common Equity (%)
Quarterly Earnings Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
0.07
0.12
0.10
0.09
0.38
2022
0.13
0.21
0.22
0.24
0.80
2023
0.28
0.36
- -
- -
- -
Quarterly Dividends Per Share
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Working Capital
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
321
199
241
Cash, Cash Equivalents & STI
298
148
179
Accounts Receivable, Net
10
33
43
Inventories
7
10
11
Total Current Liabilities
58
57
53
Payables & Accruals
58
57
47
ST Debt
0
0
0
Deferred Revenue
- -
- -
- -
Quarterly Revenue
USD

•

in mil. unless spec.
Year
Q1
Q2
Q3
Q4
FY
2021
30
36
36
38
141
2022
43
53
57
61
214
2023
85
100
- -
- -
- -
Growth Rates
USD

•

in mil. unless spec.
(avg. rate of change)
10 years
5 years
1 year
Sales/Revenue/Turnover
- -
- -
51.77%
Net Income, GAAP
-33.21%
-16.76%
112.82%
Free Cash Flow
-31.03%
-32.81%
96.61%
Total Cash Common Dividend
- -
- -
- -
Total Equity
43.78%
39.08%
44.93%
Capital Structure
USD

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
0
0
0
LT Borrowings
- -
- -
- -
LT Finance Leases
4
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
105
106
107
Market Capitalization
1,958
1,756
1,431
Legends:
Stock price
0.64
Beta (1.0 Market)
% total return 09/27
Stock
S&P500
YTD
-10.54
- -
3Y
332.29
- -
5Y
- -
- -